U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children. 미국 FDA, 영유아 침습성 폐렴구균 질환 예방을 위한 머크의 VAXNEUVANCE™(폐렴구균 15가 결합 백신) 승인
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children Save June 22, 2022 6:45 am ET Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with … Continued